Trial results

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

NCT06005012 on ClinicalTrials.gov · last registry update 2026-07-17

Closed to new participants; the 120 already enrolled are still being followed. Due to report 31 December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change in fibrosis due to NAFLD. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 25 July 2023 — 3 years so far. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

University of California, San Diego

Sponsor type

Other

Enrollment

120

Started

2023-07-25

Primary completion

2026-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in fibrosis due to NAFLD

Conditions studied

Fibrosis, Liver · Type 2 Diabetes Mellitus in Obese · Non-Alcoholic Fatty Liver Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.